(PharmaNewsWire.Com, June 27, 2017 ) A DEB, also known as a drug-coated balloon (DCB) , is an advanced technology used in the treatment of coronary and peripheral arterial diseases. These diseases cause narrowing of arteries leading to blockages. A DEB is used along with paclitaxel, an anti-proliferative drug, which helps in removing plaque from the walls of arteries and widening them. DEBs are primarily used in the treatment of two types of diseases: Peripheral arterial diseases (PADs) , and Coronary arterial diseases (CADs) .
Publisher's analysts forecast the global drug eluting balloons market to grow at a CAGR of 27.14% during the period 2017-2021. For more information about this report: http://www.reportsweb.com/global-drug-eluting-balloons-debs-market-2017-2021 . Covered in this report The report covers the present scenario and the growth prospects of the global drug eluting balloons market for 2017-2021. To calculate the market size, the report considers revenue generated from the sales of DEBs.
The market is divided into the following segments based on geography: -Americas -APAC -EMEA
Publisher's report, Global Drug Eluting Balloons Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: